Source: Lung Cancer Online | Posted 8 years ago
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNalpha in patients with metastatic melanoma
Tags:
Oral temozolomide (TMZ) followed by subcutaneous combined immunotherapy is effective in patients with metastatic melanoma, researchers in the Netherlands have found.
Toxicity linked with this treatment is manageable on an outpatient basis, report Dr G C de Gast and colleagues from the Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam.
They sought to determine both the toxicity and efficacy of oral TMZ followed by subcutaneous (sc) low-dose interleukin-2 (IL2), granulocyte-monocyte colony stimulating factor (GM-CSF) and interferon-alpha 2b (IFN alpha) in these patients. The 74 study participants received, in four separate cohorts, escalating doses of TMZ (150-250 mg m-
Comments